Evaxion Announces Business Update and First Quarter 2023 Financial Results

May 31, 2023

Press releases

Evaxion Announces Business Update and First Quarter 2023 Financial Results

Evaxion today announced its first quarter 2023 financial results and provided a business update. 

Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines

May 25, 2023

Press releases

Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines

Evaxion today unveils the technology behind its novel, proprietary genetic adjuvant developed to enhance the effectiveness of DNA and mRNA vaccines for infectious diseases and cancer.today unveils the technology behind its novel, proprietary genetic adjuvant developed to enhance the effectiveness of DNA and mRNA vaccines for infectious diseases and cancer.

Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01

May 25, 2023

Press releases

Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01

Evaxion to present promising clinical data from its EVX-01 Phase 1 clinical trial in metastatic melanoma on June 3, at the 2023 ASCO annual meeting, in Chicago, Illinois. 

Evaxion to host R&D Day on May 25, 2023

May 16, 2023

Press releases

Evaxion to host R&D Day on May 25, 2023

Read more about the event and sign up

DNA immunization with in silico predicted T-cell epitopes protects against lethal SARS-CoV-2 infection in K18-hACE2 mice

May 11, 2023

Publications

DNA immunization with in silico predicted T-cell epitopes protects against lethal SARS-CoV-2 infection in K18-hACE2 mice

Publication: Frontiers
Authors: Gry Persson, Katherine H. Restori, Julie Hincheli Emdrup, Sophie Schussek, Michael Schantz Klausen, McKayla J. Nicol, Bhuvana Katkere, Birgitte Rønø, Girish Kirimanjeswara & Anders Bundgaard Sørensen

 

Fourth quarter and full year 2022 financial results and business update

Apr 27, 2023

Press releases

Fourth quarter and full year 2022 financial results and business update

Evaxion Biotech announced today the fourth quarter and full-year 2022 financial results and provided a business update.

Evaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpoints

Apr 18, 2023

Press releases

Evaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpoints

Evaxion presented promising clinical data from its Phase 1/2a first-in-human study of its DNA-based personalized cancer immunotherapy, EVX-02 in combination with the checkpoint inhibitor nivolumab

Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platform

Apr 13, 2023

Press releases

Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platform

Evaxion today announced the successful publication in Frontiers of Immunology of preclinical data demonstrating the effectiveness of its proprietary AI-driven viral vaccine discovery platform. The presented preclinical study was conducted in collaboration with associate professor Girish Kirimanjeswara, Pennsylvania State University, US.

Interview about the ObsERV platform with Per Norlén

Apr 5, 2023

Presentations

Interview about the ObsERV platform with Per Norlén

In a 7 minutes conversation with Redeye, our CEO Per Norlén explains how leftovers from ancient viruses that infected our ancestors, so-called ERVs, can help us develop an efficient cancer treatment today and in the future.

Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients

Mar 28, 2023

Press releases

Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients

By optimizing the strategy around EVX 01, we can deliver the Phase 2b interim data in Q4 2023 as planned while deploying important clinical resources to EVX-03, where we are likely to be first in the world bringing a personalized ERV-immunotherapy to cancer patients. In addition, the focus on our core will extend our cash runway towards the end of the year.

Endogenous viral elements constitute a complementary source of antigens for personalized cancer immunotherapy

Mar 27, 2023

Publications

Endogenous viral elements constitute a complementary source of antigens for personalized cancer immunotherapy

Publication: bioRxiv
Authors: Christian Garde, Michail A Pavlidis, Pablo Garces, Emma J Lange, Sri H Ramarathinam, Mateo Sokac, Kirti Pandey, Pouya Faridi, Johanne Ahrenfeldt, Shanzou Chung, Stine Friis, Daniela Kleine-Kohlbrecher, Nicolai J Birkbak, Jens V Kringelum, Birgitte Rono, Anthony W Purcell, Thomas Trolle

Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients

Mar 23, 2023

Press releases

Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients

Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy

This potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapy

Subscribe to our Newsletter

Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.